Press & News
Press release from Boule Diagnostics AB’s Annual General Meeting on May 3, 2012
At the 2012 Annual General Meeting, the balance sheets and income statements for the Parent Company and Group were adopted for the 2011 fiscal year. The Annual General Meeting resolved that no dividend be paid for 2011 and that profits be carried forward.
The Meeting discharged the Board members and President from liability for the 2011 fiscal year.
The Meeting approved the Nomination Committee’s motion that the Board of Directors shall comprise five members, with no deputy members.
The Meeting resolved to pay Board fees according to the following: SEK 300,000 (300,000 for 2011) to the Chairman and SEK 150,000 (150,000 for 2011) to each of the remaining Board members. The amount of Board fees to be paid will thus total SEK 900,000 (900,000 for 2011). The Meeting also resolved to reserve SEK 35,000 (35,000 for 2011) to be distributed by the Chairman for committee work as applicable. If the Chairman of the Board is a member of a committee, he is entitled to the same fees as the other members of the committee. Board members are entitled to invoice Board fees on condition that they are taxable and cost-neutral for the company. It was also resolved that fees to auditors will be paid according to continuous invoicing, as in the past.
The Annual General Meeting resolved to re-elect Lars-Olof Gustavsson, Britta Dalunde, Eva-Lotta Kraft, Åke Nygren and Gösta Oscarsson as Board members for the period until the end of the next Annual General Meeting. Lars-Olof Gustavsson was re-elected Chairman of the Board.
The Meeting also approved the proposed instructions for the Nomination Committee.
The Meeting approved the Board of Directors’ motion for guidelines for remuneration to senior executives.
Complete motions pertaining to the Annual General Meeting’s resolutions above are available on Boule’s website, www.boule.se.
For further information, please contact:
Lars-Olof Gustavsson, Chairman of the Board of Boule Diagnostics AB,
tel: +46 (0)8-14 54 20
Ernst Westman, President and CEO of Boule Diagnostics AB,
tel: +46 (0)708-60 88 63
The information in this press release is such that Boule Diagnostics AB is obligated to publish in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on May 4, 2012, at 8:00 a.m.
About Boule Diagnostics AB
Boule Diagnostics AB is a rapidly growing diagnostic company that develops, manufactures and sells systems and consumer products for complete blood counts (hematology) to non-institutional healthcare. The company focuses primarily on small and mid-sized hospitals, clinics and laboratories in non-institutional healthcare, as well as other diagnostic companies in both human and veterinary hematology. The operation is conducted through commercial subsidiaries in Sweden, the US and China. Boule Diagnostic’s share has been listed on NASDAQ OMX Stockholm since 2011.